Composition of Balance Sheet Items (Tables)

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of inventories

Inventories, Net

	March 31, 2022		December 31, 2021
	(unaudited)
Raw materials	$	9,239	$	7,325
Work in process	46,219		45,711
Finished goods	33,337		32,923
Total	$	88,795	$	85,959

Schedule of property and equipment

Property and Equipment, Net

	March 31, 2022		December 31, 2021
	(unaudited)
Lab equipment and furniture	$	12,199	$	12,287
Leasehold improvements	13,998		14,369
Software	2,185		4,776
Computer equipment	1,282		1,944
Construction-in-progress	32		33
	29,696		33,409
Less accumulated depreciation and amortization	(12,481)		(16,454)
Property and equipment, net	$	17,215	$	16,955

Schedule of accrued expenses and other current liabilities

Accounts Payable and Accrued Liabilities

	March 31, 2022		December 31, 2021
	(unaudited)
Accounts payable	$	12,323	$	9,331
Accrued professional fees	16,209		26,728
Accrued compensation	14,555		28,068
Accrued product costs	12,727		18,460
Accrued royalties (1)	11,044		13,821
Accrued clinical trial costs (2)	7,784		9,125
Operating lease liabilities, current portion (3)	6,141		6,477
Other accrued expenses	8,649		5,673
Total	$	89,432	$	117,683

_______________________________

(1) Refer to Note 16, Commitments and Contingencies.

(2) Includes preclinical and all clinical trial-related costs.

(3) Refer to Note 13, Leases.

Schedule of accrued product returns and rebates

Accrued Product Returns and Rebates

	March 31, 2022		December 31, 2021
	(unaudited)
Accrued product rebates	$	104,948	$	97,597
Accrued product returns	35,233		35,127
Total	$	140,181	$	132,724

Other liabilities

Other Liabilities

	March 31, 2022		December 31, 2021
	(unaudited)
Nonrecourse liability related to sale of future royalties, long-term	$	3,784	$	5,977
Other liabilities	10,361		10,403
Total	$	14,145	$	16,380